Nurix Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Nurix Therapeutics
NRIX Stock  USD 17.59  0.02  0.11%   
Nurix Therapeutics financial statements provide useful quarterly and yearly information to potential Nurix Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nurix Therapeutics financial statements helps investors assess Nurix Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nurix Therapeutics' valuation are summarized below:
Gross Profit
-167.1 M
Market Capitalization
1.3 B
Enterprise Value Revenue
13.8145
Revenue
54.5 M
Earnings Share
(2.88)
We have found one hundred twenty available fundamental ratios for Nurix Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Nurix Therapeutics last-minute market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.4 B in 2025. Enterprise Value is likely to rise to about 1.3 B in 2025

Nurix Therapeutics Total Revenue

44.99 Million

Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 326 K, Net Interest Income of 23.8 M or Interest Income of 23.8 M, as well as many indicators such as Price To Sales Ratio of 24.85, Dividend Yield of 0.0 or PTB Ratio of 2.66. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Nurix Therapeutics Correlation against competitors.
For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Nurix Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets808.2 M769.7 M268.8 M
Slightly volatile
Other Current Liabilities44.4 M42.3 M11.7 M
Slightly volatile
Total Current Liabilities64.9 M110.2 M51.1 M
Slightly volatile
Other Liabilities42.9 M41.4 M22.5 M
Slightly volatile
Property Plant And Equipment Net55.4 M52.8 M18.9 M
Slightly volatile
Current Deferred Revenue37.1 M44.1 M32.3 M
Slightly volatile
Accounts Payable13.9 M13.2 M4.5 M
Slightly volatile
Cash76.9 M126.5 M54.5 M
Slightly volatile
Non Current Assets Total75.6 M57.4 M40.5 M
Slightly volatile
Non Currrent Assets Other2.8 M4.7 M1.7 M
Slightly volatile
Other Assets5.4 M5.7 M7.7 M
Pretty Stable
Cash And Short Term Investments736.1 M701 M223.2 M
Slightly volatile
Common Stock Total Equity30.4 K54 K21.1 K
Slightly volatile
Common Stock Shares Outstanding44.6 M77.2 M32.4 M
Slightly volatile
Short Term Investments603.3 M574.5 M165.2 M
Slightly volatile
Liabilities And Stockholders Equity808.2 M769.7 M268.8 M
Slightly volatile
Non Current Liabilities Total48.2 M41.8 M53.6 M
Very volatile
Capital Surpluse856.4 M815.6 M298.5 M
Slightly volatile
Other Current Assets7.1 M11.3 M4.7 M
Slightly volatile
Total Liabilities131.2 M163.7 M106.6 M
Slightly volatile
Property Plant And Equipment Gross97.1 M92.5 M27.8 M
Slightly volatile
Total Current Assets747.9 M712.3 M229.2 M
Slightly volatile
Capital Stock91.8 K87.4 K28.9 K
Slightly volatile
Non Current Liabilities Other25.2 M48.8 M17.6 M
Slightly volatile
Net Working Capital632.2 M602.1 M174.9 M
Slightly volatile
Short Term Debt8.8 M9.2 M5.9 M
Slightly volatile
Common Stock91.8 K87.4 K28.9 K
Slightly volatile
Property Plant Equipment12.6 M19.7 M9.7 M
Slightly volatile
Net Receivables684 K720 K7.7 M
Slightly volatile
Short and Long Term Debt Total23.1 M32.5 M16.9 M
Slightly volatile
Deferred Long Term Liabilities400 K450 K490.6 K
Slightly volatile

Nurix Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income23.8 M22.7 M5.6 M
Slightly volatile
Interest Income23.8 M22.7 M5.6 M
Slightly volatile
Depreciation And Amortization16.5 M15.7 M6.6 M
Slightly volatile
Interest Expense17.3 M16.5 M5.9 M
Slightly volatile
Selling General Administrative29.8 M52.8 M19.9 M
Slightly volatile
Total Revenue45 M62.7 M41 M
Slightly volatile
Other Operating Expenses165.5 M307.7 M116 M
Slightly volatile
Research Development135.7 M254.9 M96.1 M
Slightly volatile
Total Operating Expenses165.5 M307.7 M116 M
Slightly volatile
Reconciled Depreciation19.8 M18.9 M7.1 M
Slightly volatile
Total Other Income Expense Net23.8 M22.7 M5.6 M
Slightly volatile
Cost Of Revenue228.4 M217.5 M82.1 M
Slightly volatile
Non Operating Income Net Other2 M4 M1.8 M
Slightly volatile
Selling And Marketing Expenses4.9 M5.5 M6 M
Slightly volatile

Nurix Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation41 M39 M12.5 M
Slightly volatile
Begin Period Cash Flow62.7 M63.9 M40.2 M
Slightly volatile
Capital Expenditures6.8 M10.7 M4.5 M
Slightly volatile
Total Cash From Financing Activities586.4 M558.5 M140.5 M
Slightly volatile
End Period Cash Flow77.5 M127.5 M54.9 M
Slightly volatile
Change To Netincome34.2 M32.6 M10.9 M
Slightly volatile
Change To Inventory7.2 M6.1 M9.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio24.8531.2916.9693
Slightly volatile
Days Sales Outstanding17087.53180
Slightly volatile
Stock Based Compensation To Revenue0.30.560.2205
Slightly volatile
EV To Sales16.4823.1414.7667
Slightly volatile
Payables Turnover20.4433.9825.8829
Slightly volatile
Sales General And Administrative To Revenue0.540.760.4588
Slightly volatile
Research And Ddevelopement To Revenue2.463.662.1977
Slightly volatile
Capex To Revenue0.130.150.1072
Slightly volatile
Cash Per Share5.68.174.9815
Slightly volatile
Days Payables Outstanding10.5611.1246.3533
Pretty Stable
Net Debt To EBITDA0.420.442.2686
Slightly volatile
Current Ratio3.375.822.9561
Slightly volatile
Receivables Turnover2.544.322.6092
Slightly volatile
Graham Number14.320.3112.3884
Slightly volatile
Debt To Equity0.05680.04830.0481
Slightly volatile
Capex Per Share0.130.120.1282
Slightly volatile
Revenue Per Share1.250.931.6523
Slightly volatile
Interest Debt Per Share0.30.380.3284
Slightly volatile
Debt To Assets0.03690.03810.0333
Slightly volatile
Days Of Payables Outstanding10.5611.1246.3533
Pretty Stable
Ebt Per Ebit1.051.040.9484
Slightly volatile
Long Term Debt To Capitalization0.02970.03340.0364
Slightly volatile
Total Debt To Capitalization0.05160.04590.0451
Slightly volatile
Debt Equity Ratio0.05680.04830.0481
Slightly volatile
Quick Ratio3.375.822.9571
Slightly volatile
Net Income Per E B T1.031.151.0155
Pretty Stable
Cash Ratio1.51.321.1123
Slightly volatile
Days Of Sales Outstanding17087.53180
Slightly volatile
Fixed Asset Turnover1.31.375.4004
Slightly volatile
Debt Ratio0.03690.03810.0333
Slightly volatile
Price Sales Ratio24.8531.2916.9693
Slightly volatile
Asset Turnover0.0890.09370.4992
Slightly volatile

Nurix Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 B1.3 B640.9 M
Slightly volatile
Enterprise Value1.3 B1.3 B594.9 M
Slightly volatile

Nurix Fundamental Market Drivers

Cash And Short Term Investments609.6 M

Nurix Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
11th of April 2024
Next Financial Report
View
30th of November 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
31st of August 2023
Last Quarter Report
View
30th of November 2022
Last Financial Announcement
View

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue44.1 M37.1 M
Total Revenue62.7 M45 M
Cost Of Revenue217.5 M228.4 M
Stock Based Compensation To Revenue 0.56  0.30 
Sales General And Administrative To Revenue 0.76  0.54 
Research And Ddevelopement To Revenue 3.66  2.46 
Capex To Revenue 0.15  0.13 
Revenue Per Share 0.93  1.25 
Ebit Per Revenue(4.49)(4.72)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CSXCSX Corporation
ETONEton Pharmaceuticals
ALLTAllot Communications

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY